cas 107228-51-3|| where to buy 3,6-dichloro-4-propan-2-ylpyridazine

Nombre del producto:3,6-dichloro-4-propan-2-ylpyridazine

IUPAC Name:3,6-dichloro-4-(propan-2-yl)pyridazine

Unidad de embalaje	Stock disponible	Precio($)
CM327927-10g	in stock	ƚƴƴ
CM327927-50g	in stock	ĳŤƴŮ
CM327927-100g	in stock	ƴƈƴħ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 107228-51-3 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :107228-51-3; Fórmula molecular:C7H8Cl2N2; Punto de fusión:-; Código de sonrisas:CC(C1=CC(Cl)=NN=C1Cl)C; Densidad:

: Número de catálogo:CM327927; Peso molecular:191.06; Punto de ebullición:; Nº Mdl:; Almacenamiento:

: Pyridazines; Pyridazine, also known as o-diazobenzene, is a six-membered heterocyclic compound containing two nitrogen heteroatoms in the 1 and 2 positions with a special structure and a wide biological activity. Pyridazine is more and more popular in drug development, and a variety of pyridazine drugs have been developed and marketed. From the perspective of the therapeutic field, pyridazine drug molecules are mainly used for tumor treatment, but also involve in many therapeutic fields such as inflammation, hypertension and cardiovascular disease. With the increase and in-depth of research, pyridazine drugs will play more roles in the treatment of diseases.

: Resmetirom; Sept. 13, 2023, Madrigal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for resmetirom for the treatment of adult patients with NASH with liver fibrosis.
Nonalcoholic steatohepatitis (NASH) is a more advanced form of nonalcoholic fatty liver disease (NAFLD).
Resmetirom is designed to target the underlying causes of NASH by reducing or eliminating liver fat (steatosis) as well as reducing liver inflammation, liver cell ballooning (hepatocyte cell death), and liver fibrosis that can lead to cirrhosis. Resmetirom is the only orally administered, small-molecule, liver-directed, truly β-selective THR agonist in Phase 3 development.

: ALG-055009; Aligos Therapeutics announced positive topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects. ALG-055009 demonstrated a favorable tolerability profile with no serious adverse events (SAEs), or clinical hyper/hypothyroidism. The majority of treatment emergent adverse events (TEAEs) were mild to moderate, with one discontinuation due to worsening insomnia in a subject with pre-existing insomnia.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.